$578 M

PRVL Mkt cap, 27-May-2020
Prevail Therapeutics Net income (Q1, 2020)-18.6 M
Prevail Therapeutics EBIT (Q1, 2020)-19.3 M
Prevail Therapeutics Cash, 31-Mar-2020149.6 M
Prevail Therapeutics EV439.4 M

Prevail Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

R&D expense

995.4k14.1m48.8m

General and administrative expense

803.7k4.7m17.0m

Operating expense total

1.8m18.8m65.8m

EBIT

(1.8m)(18.8m)(65.8m)

Interest expense

27.5k471.1k

Interest income

12.0886.7k2.6m

Net Income

(1.8m)(19.1m)(63.2m)

Quarterly

USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

R&D expense

1.3m8.4m12.0m16.8m11.4m

General and administrative expense

641.2k1.9m3.7m4.5m7.9m

Operating expense total

1.9m10.3m15.7m21.3m19.3m

EBIT

(1.9m)(10.3m)(15.7m)(21.3m)(19.3m)

Interest expense

471.1k

Interest income

11.0351.3k565.0k989.0k494.0k

Net Income

(3.2m)(9.9m)(15.1m)(20.3m)(18.6m)

Prevail Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

12.7m63.0m168.1m

Prepaid Expenses

104.7k562.7k6.4m

Current Assets

12.8m63.6m174.5m

PP&E

106.1k677.9k2.5m

Total Assets

14.3m72.9m187.1m

Accounts Payable

265.4k1.2m5.2m

Short-term debt

3.2m917.5k1.3m

Current Liabilities

10.7m3.6m11.8m

Long-term debt

1.0m8.0m9.9m

Total Debt

4.3m8.9m11.3m

Total Liabilities

11.7m11.6m21.8m

Common Stock

445.0445.03.0k

Preferred Stock

3.5m79.7m

Additional Paid-in Capital

885.7k2.5m249.4m

Retained Earnings

(1.8m)(20.9m)(84.1m)

Total Equity

2.6m58.8m165.3m

Debt to Equity Ratio

1.7 x0.2 x

Debt to Assets Ratio

0.3 x0.1 x

Financial Leverage

5.5 x1.2 x1.1 x

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

100.3m202.1m183.1m149.6m

Prepaid Expenses

4.4m4.3m7.4m4.9m

Current Assets

104.7m206.3m190.5m154.5m

PP&E

897.5k2.1m2.5m2.7m

Total Assets

115.2m216.1m203.4m168.8m

Accounts Payable

3.2m2.0m5.0m3.9m

Short-term debt

1.1m1.4m

Current Liabilities

5.8m7.7m11.2m10.8m

Long-term debt

7.6m7.4m10.2m9.6m

Total Debt

8.7m7.4m10.2m10.9m

Total Liabilities

13.4m15.0m21.4m20.3m

Common Stock

445.03.0k3.0k3.0k

Preferred Stock

129.5m

Additional Paid-in Capital

3.1m247.0m248.3m251.1m

Retained Earnings

(30.9m)(46.0m)(66.3m)(102.7m)

Total Equity

98.7m201.0m182.0m148.5m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.2 x1.1 x1.1 x1.1 x

Prevail Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(1.8m)(19.1m)(63.2m)

Depreciation and Amortization

2.0k54.9k265.0k

Accounts Payable

265.4k976.0k3.9m

Cash From Operating Activities

(987.3k)(14.0m)(55.8m)

Purchases of PP&E

(108.1k)(626.7k)(2.1m)

Cash From Investing Activities

(108.1k)(626.7k)(2.1m)

Dividends Paid

Cash From Financing Activities

13.9m64.9m162.9m

Net Change in Cash

12.8m50.3m105.0m

Quarterly

USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(3.2m)(9.9m)(25.0m)(45.3m)(18.6m)

Depreciation and Amortization

5.1k36.8k93.0k201.0k111.0k

Accounts Payable

459.7k713.2k762.0k3.7m(1.2m)

Cash From Operating Activities

(1.2m)(12.3m)(22.5m)(41.0m)(18.2m)

Purchases of PP&E

(21.0k)(256.4k)(1.5m)(2.0m)(287.0k)

Cash From Investing Activities

(21.0k)(256.4k)(1.5m)(2.0m)(287.0k)

Cash From Financing Activities

56.9m49.8m163.1m163.1m62.0k

Net Change in Cash

55.7m37.3m139.1m120.1m(18.5m)

Prevail Therapeutics Ratios

USDY, 2020

EV/EBIT

-22.8 x

EV/CFO

-24.1 x

Financial Leverage

1.1 x